339 related articles for article (PubMed ID: 29903623)
1. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
2. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
3. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
4. [A case of myasthenia gravis and myositis induced by nivolumab].
Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M
Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):263b. PubMed ID: 29176295
[No Abstract] [Full Text] [Related]
6. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
8. Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy.
Katyal N; Katsumoto TR; Ramachandran KJ; Yunce M; Muppidi S
J Clin Neuromuscul Dis; 2023 Dec; 25(2):89-93. PubMed ID: 37962196
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced myositis: A case report and a literature review.
Bourgeois-Vionnet J; Joubert B; Bernard E; Sia MA; Pante V; Fabien N; Honnorat J; Streichenberger N
J Neurol Sci; 2018 Apr; 387():51-53. PubMed ID: 29571871
[No Abstract] [Full Text] [Related]
10. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
12. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Cooper DS; Meriggioli MN; Bonomi PD; Malik R
J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab.
Cortellini A; Napoleoni L; Cimini N; Parisi A; Pavese F; DʼOrazio C; Verna L; Porzio G; Ficorella C
J Clin Neuromuscul Dis; 2018 Dec; 20(2):99-100. PubMed ID: 30439756
[No Abstract] [Full Text] [Related]
14. Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis.
Tan RYC; Toh CK; Takano A
J Thorac Oncol; 2017 Jul; 12(7):e90-e91. PubMed ID: 28629544
[No Abstract] [Full Text] [Related]
15. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
Kao JC; Brickshawana A; Liewluck T
Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
18. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
19. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
20. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
